A surprise trial failure involving AstraZeneca and Ionis’ Wainua (eplontersen) has put pressure on RNA-targeting “silencer” therapies for TTR cardiomyopathy. Data discussed in connection with the European Society of Cardiology meeting showed the program missed its outcome goals, triggering renewed debate over whether the approach adds meaningful benefit on top of standard care. STAT+ reporting points to complexity in interpreting the results, including factors such as co-therapy use by some participants. Investors appear to be recalibrating expectations across the ATTR-CM segment, with Alnylam closely watching the competitive implications for RNA therapeutics.